Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Podobne zapisy

• Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
  od: Stopeck, Alison T., i wsp.
  Wydane: (2015)
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
  od: Fizazi, Karim, i wsp.
  Wydane: (2011)
• Denosumab and Bone Metastasis-Free Survival in Men With Castration-Resistant Prostate Cancer: Results of a Global Phase 3, Randomised, Placebo-Controlled Trial
  od: Smith, Matthew R, i wsp.
  Wydane: (2011)
• Impact of denosumab on bone mass in cancer patients
  od: Brown-Glaberman, Ursa, i wsp.
  Wydane: (2013)
• Response to letter to the Editors—Safety of long-term denosumab therapy
  od: Stopeck, Alison T., i wsp.
  Wydane: (2016)